Proton Therapy

Bozeman, MT, United States

Proton Therapy

Bozeman, MT, United States
SEARCH FILTERS
Time filter
Source Type

DUBLIN, May 9, 2017 /PRNewswire/ -- Research and Markets has announced the addition of the "Europe Proton Therapy Market & Forecast, Patients Treated at Proton Therapy Centers, Reimbursement Policy" report to their offering. Europe Proton Therapy Market has a market...


News Article | May 10, 2017
Site: globenewswire.com

Louvain-La-Neuve, Belgium, May 10, 2017 - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, today provides a trading update for the first quarter ending 31 March 2017. Olivier Legrain, Chief Executive Officer of IBA, commented: "We are pleased to have made good progress in this first quarter of 2017 and are on track to meet our growth targets. Dosimetry has seen a good recovery across all regions and is now positively contributing to our REBIT. Our production expansion and regionalization strategy to meet growing global demand continues to be rolled out and we are currently installing eight projects across the globe and getting ready to install another 17 internationally. "In Proton Therapy, however, several recent delays in project execution caused by customer building delays lead us to slightly adjust our full year guidance for 2017. While our guidance on revenue growth remains unchanged at around 15% to 20%, the project execution delays impact our revenue recognition and, to some extent, our operational leverage. Due to this, we revise our guidance on REBIT to between 10% and 12% for 2017, and around 13% for 2018. "We are confident in the strong prospects for IBA in 2017 and beyond due to our growth strategy, the significant market potential in proton therapy and our focus on maintaining the world's leading proton therapy offering." IBA reported the following segmental trends and news during the first quarter of 2017: Proton therapy's penetration of the radiation therapy market continues to grow due to increasing interest from the clinical community, affordability and technological advances. To keep ahead of and to lead this growth, IBA continues to scale up production capacity, including investment in a new superconducting synchrocyclotron assembly line (for Proteus®ONE*), and a new customer center, with an expected further combined CAPEX of about EUR 16 million, of which around EUR 10 million will be invested in 2017. The Company is also recruiting an additional 200 engineers and qualified staff, worldwide, through 2017. IBA has a high backlog of EUR 316 million and the sustainable revenue source from service and maintenance contracts now represents EUR 673 million of revenue over the next 10-15 years. IBA expects to achieve revenue growth of between 15% to 20% in 2017 and double digit thereafter. The Company expects its operating margin to be 10% to 12% in 2017, increasing to around 13% by 2018 and stabilizing at around 15% by 2020. IBA is planning to maintain a dividend payout ratio of 30%. This guidance is not only based upon the continued expected growth of the proton therapy market but also the balance between the economies of scale that we can achieve at a higher production rate. In addition, the growing importance of service revenue versus the increased demand driven by the equipment price tag reduction in the proton therapy market and our continued investment in R&D and software capabilities are anticipated to be contributing factors. In accordance with the Royal Decree of 14 November 2007, IBA indicates that this Trading Update has been prepared by the Chief Executive Officer (CEO) and the Chief Financial Officer (CFO). About IBA IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com *Proteus®ONE and Proteus®PLUS are brand names of Proteus 235 For further information, please contact:


Asia Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022 provides a comprehensive assessment of the fast-evolving, high-growth Proton Therapy Market. Asia proton therapy market is anticipated to almost three-fold during the period 2016 - 2022. The number of proton therapy centers is continuously increasing in Asia. Still, it is believed that players will miss out on a majority of cancer patients who can benefit with proton therapy, overlooking a huge multi-Billion-dollar potential market. The number of patients treated with Proton Therapy is very low whereas; the potential candidates for proton therapy are huge. Key Points Covered in the Report: - Asia accounts for around 60% of the world population and half the global burden of cancer. - Mitsubishi is the leading player in proton therapy market in Japan. However, other players like IBA, Hitachi, Sumitomo etc. have also started to make their presence felt in the market. - South Korea is the second largest market for proton therapy in Asia. - China has the huge market opportunity for proton therapy treatment owing to large population bae of cancer patients. - IBA has one operational proton therapy center in China while 4 more centers are in development phase. - In India, 2 proton therapy centers are under development phase and are scheduled to open in 2018 and 2019. Key Topics Covered: 1. Executive Summary 2. Asia Proton Therapy Market Analysis 2.1 Asia Proton Therapy Market - Actual and Potential Market 2.2 Asia Proton Therapy Patient Number - Actual and Potential 3. Asia Proton Therapy Market Share Analysis 3.1 Asia Proton Therapy Actual and Potential Market Share - By Country 3.2 Asia Proton Therapy Actual and Potential Candidate Share - By Country 4. Asia - List of Proton Therapy Centers, Start of Treatment, Patient Treated 5. Japan Proton Therapy Market Analysis 5.1 Japan Proton Therapy - Actual and Potential Market (2003 - 2022) 5.2 Japan Proton Therapy Patients Number - Actual and Potential (2003 - 2022) 5.3 Japan - List of Proton Therapy Centers, Cost, Start of Treatment, Patient Treated 5.4 Japan Proton Therapy - Company Analysis 6. Japan - Number of Patients Treated at Proton Therapy Centers 6.1 National Institute of Radiological Sciences - Number of Patients Treated (2008 - 2015) 6.2 Hyogo Ion Beam Medical Center - Number of Patients Treated (2007 - 2015) 6.3 Shizuoka Cancer Center - Number of Patients Treated (2007 - 2015) 6.4 Southern Tohoku Proton Therapy Center - Number of Patients Treated (2013 - 2014) 6.5 Gunma University Heavy Ion Medical Center - Number of Patients Treated (2013 - 2015) 6.6 Fukui Prefectural Hospital Proton Beam Cancer Treatment Center - Number of Patients Treated (2013 - 2015) 6.7 Medipolis Medical Research Institute - Number of Patients Treated (2013 - 2015) 6.8 Saga Heavy Ion Medical Accelerator in Tosu - Number of Patients Treated (2013 - 2015) 6.9 Japanese National Cancer Center - Number of Patients Treated (2007 - 2014) 6.10 The Proton Medical Research Center 2, University of Tsukuba, JAPAN - Number of Patients Treated (2007 - 2015) 6.11 Nagoya City Quality Life 21 Jouhoku, Japan - Number of Patients Treated (2013 - 2015) 6.12 Aizawa Hospital - Number of Patients Treated (Oct - 2014) 7. South Korea Proton Therapy Market Analysis 7.1 South Korea Proton Therapy - Actual and Potential Market (2007 - 2022) 7.2 South Korea Proton Therapy Patients Number - Actual and Potential (2007 - 2022) 7.3 South Korea - List of Proton Therapy Centers, Start of Treatment, Patient Treated 8. South Korea - Number of Patients Treated at Proton Therapy Centers 8.1 Korean National Cancer Center - Number of Patients Treated (2007 - 2015) 8.2 Samsung Proton Center - Number of Patients Treated (2015) 9. China Proton Therapy Market Analysis 9.1 China Proton Therapy - Actual and Potential Market (2014 - 2022) 9.2 China Proton Therapy Patients Number - Actual and Potential (2014 - 2022) 9.3 China - List of Proton Therapy Centers, Start of Treatment 10. China - Number of Patients Treated at Proton Therapy Centers 10.1 Wanjie Proton Therapy Center (WPTC) - Number of Patients Treated (2007 - 2013) 11. India Potential Proton Therapy Market Analysis (2009 - 2022) 11.1 India - Potential Proton Therapy Market and Forecast 11.2 India - Potential Candidate for Proton Therapy Number and Forecast 11.3 India - List of Proton Therapy Centers, Start of Treatment 12. Singapore Potential Proton Therapy Market Analysis (2012 - 2022) 12.1 Singapore - Potential Proton Therapy Market and Forecast 12.2 Singapore - Potential Candidate for Proton Therapy Number and Forecast 12.3 Singapore - List of Proton Therapy Centers, Start of Treatment 13. Taiwan Potential Proton Therapy Market Analysis (2012 - 2022) 13.1 Taiwan - Potential Proton Therapy Market and Forecast 13.2 Taiwan - Potential Candidate for Proton Therapy Number and Forecast 13.3 Taiwan - List of Proton Therapy Centers, Start of Treatment 14. Current Radiation Therapies 14.1 Third Dimensional Conformal Therapy (CRT) 14.2 Image Guided Radiotherapy (IGRT) 14.3 Intensity Modulated Radiotherapy (IMRT) 14.4 Stereotactic Radiotherapy 14.5 Neutron Therapy 14.6 Heavy Ion Radiotherapy 14.7 Proton Therapy 15. Components of a Standard Proton Therapy Center 15.1 Proton Accelerator 15.2 Beam Transport System 15.3 Beam Delivery System 15.4 Nozzle 15.5 Treatment Planning System 15.6 Image Viewers 15.7 Patient Positioning System (PPS) 15.8 Human Resource 16. Proton Therapy - Driving Factors 16.1 Technology Advancement 16.2 Growing Incidence of Cancer Patients 16.3 Proton Therapy Provides Enormous Benefits 17. Proton Therapy - Challenges 17.1 Requires Huge Investment 17.2 Operations Challenges 17.3 More Clinical Evidence Is Needed For more information about this report visit http://www.researchandmarkets.com/research/8hcbbg/asia_proton Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/asia-proton-therapy-market-report-2017-patients-treated-list-of-proton-therapy-centers-and-forecast-to-2022---research-and-markets-300454204.html


DUBLIN, May 9, 2017 /PRNewswire/ -- Research and Markets has announced the addition of the "Asia Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022" report to their offering. Asia Proton Therapy Market (Actual...


News Article | May 9, 2017
Site: www.prnewswire.com

China Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022 provides a comprehensive assessment of the fast-evolving, high-growth Proton Therapy Market. Cancer incidence and mortality have been increasing in China, making cancer the leading cause of death since 2010 and a major public health problem in the country. With an increasing incidence of cancer, there is a definite need for novel, cutting edge, treatment methods, such as, Proton Therapy. Unfortunately, the access to proton therapy is limited for a vast population, owing to a low number of proton therapy centers. Hence, many research institutions and hospitals have now started investing in proton therapy to make it more accessible to patients. There are currently two operational proton therapy centers in China. IBA has one operational proton therapy center in China while 4 more centers are in development phase. Key Topics Covered: 1. Executive Summary 2. China Proton Therapy Market Analysis 2.1 China Proton Therapy - Actual and Potential Market (2014 - 2022) 2.2 China Proton Therapy Patients Number - Actual and Potential (2014 - 2022) 3. China - List of Proton Therapy Centers, Start of Treatment 4. China - Number of Patients Treated at Proton Therapy Centers 4.1 Wanjie Proton Therapy Center (WPTC) - Number of Patients Treated (2007 - 2013) 4.2 Shanghai Proton & Heavy Ion Center (SPHIC) - Number of Patients Treated (2014 - 2015) 5. Current Radiation Therapies 5.1 Third Dimensional Conformal Therapy (CRT) 5.2 Image Guided Radiotherapy (IGRT) 5.3 Intensity Modulated Radiotherapy (IMRT) 5.4 Stereotactic Radiotherapy 5.5 Neutron Therapy 5.6 Heavy Ion Radiotherapy 5.7 Proton Therapy 6. Components of a Standard Proton Therapy Center 6.1 Proton Accelerator 6.2 Beam Transport System 6.3 Beam Delivery System 6.4 Nozzle 6.5 Treatment Planning System 6.6 Image Viewers 6.7 Patient Positioning System (PPS) 6.8 Human Resource 7. Proton Therapy - Driving Factors 7.1 Technology Advancement 7.2 Growing Incidence of Cancer Patients 7.3 Proton Therapy Provides Enormous Benefits 8. Proton Therapy - Challenges 8.1 Requires Huge Investment 8.2 Operations Challenges 8.3 More Clinical Evidence Is Needed For more information about this report visit http://www.researchandmarkets.com/research/p5z2hf/china_proton Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/china-proton-therapy-market-report-2017-2022---research-and-markets-300454193.html


DUBLIN, May 9, 2017 /PRNewswire/ -- Research and Markets has announced the addition of the "Japan Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022" report to their offering. Japan proton therapy market is...


Europe Proton Therapy Market has a market potential of much more than US$ 10 Billion in 2016 In the year 2009 France used be have the highest proton therapy market share. But by 2012 Germany replaced France from the top position and it continues to hold its top position in 2016 as well. According to research, by the year 2019 Germany will no longer be holding the top position in Europe Proton Therapy Market. Russia will be an interesting country to watch in future as its proton therapy market share will make a jump from 7th position in 2017 to 4th position in 2021. Key Topics Covered: 1. Executive Summary 2. Europe Proton Therapy Market (Actual & Potential) 3. Europe Proton Therapy Patient Number - Actual and Potential 4. By Countries - Europe Proton Therapy Market Share 5. Europe - List of Proton Therapy Centers 6. Europe - Proton Therapy Treated Patients by Centers (Country wise) 7. Germany Proton Therapy Market - Actual & Potential Market 8. Germany Proton Therapy Patient Number - Actual and Potential 9. France Proton Therapy Market - Actual & Potential Market 10. France Proton Therapy Patient Number - Actual and Potential 11. Italy Proton Therapy Market - Actual & Potential Market 12. Italy Proton Therapy Patient Number - Actual and Potential 13. United Kingdom Proton Therapy Market - Actual & Potential Market 14. United Kingdom Proton Therapy Patient Number - Actual and Potential 15. Switzerland Proton Therapy Market - Actual & Potential Market 16. Switzerland Proton Therapy Patient Number - Actual and Potential 17. Russia Proton Therapy Market - Actual & Potential Market 18. Russia Proton Therapy Patient Number - Actual and Potential 19. Sweden Proton Therapy Market - Actual & Potential Market 20. Sweden Proton Therapy Patient Number - Actual and Potential 21. Poland Proton Therapy Market - Actual & Potential Market 22. Poland Proton Therapy Patient Number - Actual and Potential 23. Proton Therapy - Reimbursement Policies 24. Components of a Standard Proton Therapy Center 25. Global Proton Therapy - Company Analysis (2010-2021) 27. Proton Therapy - Challenges Companies Mentioned - Elekta - IBA - Varian Medical Systems For more information about this report visit http://www.researchandmarkets.com/research/l2bnng/europe_proton Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/europe-proton-therapy-market--forecast-report-2017-patients-treated-at-proton-therapy-centers-reimbursement-policy-2010-2021---research-and-markets-300454124.html


News Article | May 9, 2017
Site: www.prnewswire.co.uk

DUBLIN, May 9, 2017 /PRNewswire/ -- Research and Markets has announced the addition of the "China Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022" report to their offering. China Proton Therapy Market (Actual...


Japan proton therapy market is anticipated to grow at a CAGR of around 18% during the period 2017 - 2022. The number of proton therapy centers is continuously increasing in Japan. Still, it is believed that players will miss out on a majority of cancer patients who can benefit with proton therapy, overlooking a huge multi-Billion-dollar potential market. The number of patients treated with Proton Therapy is very low whereas; the potential candidates for proton therapy are huge. Mitsubishi is the leading player in proton therapy market in Japan. However, other players like IBA, Hitachi, Sumitomo etc. have also started to make their presence felt in the market. Mitsubishi Electric has installed systems at 9 of the proton therapy facilities in Japan. The report titled Japan Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022 provides a comprehensive assessment of the fast-evolving, high-growth Proton Therapy Market. Key Topics Covered: 1. Executive Summary 2. Japan Proton Therapy Market Analysis 3. Japan - List of Proton Therapy Centers, Cost, Start of Treatment, Patient Treated 4. Japan Proton Therapy - Company Analysis 5. Japan - Number of Patients Treated at Proton Therapy Centers 6. Current Radiation Therapies 7. Components of a Standard Proton Therapy Center 8. Proton Therapy - Driving Factors 9. Proton Therapy - Challenges For more information about this report visit http://www.researchandmarkets.com/research/8kxzwg/japan_proton Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/japan-proton-therapy-market-actual--potential-market-2017-2022-mitsubishi-is-the-leading-player---research-and-markets-300454171.html


Farace P.,Proton Therapy
Physics in Medicine and Biology | Year: 2014

A two-steps procedure is presented to convert dual-energy CT data to stopping power ratio (SPR), relative to water. In the first step the relative electron density (RED) is calculated from dual-energy CT-numbers by means of a bi-linear relationship: RED = a HUscH + b HUscL + c, where HUscH and HUscL are scaled units (HUsc = HU + 1000) acquired at high and low energy respectively, and the three parameters a, b and c has to be determined for each CT scanner. In the second step the RED values were converted into SPR by means of published poly-line functions, which are invariant as they do not depend on a specific CT scanner. The comparison with other methods provides encouraging results, with residual SPR error on human tissue within 1%. The distinctive features of the proposed method are its simplicity and the generality of the conversion functions. © 2014 Institute of Physics and Engineering in Medicine.

Loading Proton Therapy collaborators
Loading Proton Therapy collaborators